XERIS BIOPHARMA HOLDINGS, INC.
Ownership & governance
Executives 5Directors 8Avg age 60Avg tenure 2.8y
JS
John Shannon
Chief Executive Officer
Age 64Since 2024-07-31Profile →
+12
Executives5
Board of directors8
BB
Barbara-Jean Bormann-Kennedy→
Director/Board Member
Age 67Since 2021-10-04
DH
Dawn Halkuff→
Director/Board Member
Age 55Since 2021-10-04
MP
Marla Persky→
Chairman
Age 70Since 2024-07-31
JJ
John Johnson→
Director/Board Member
Age 68Since 2021-10-04
GK
Garheng Albert Kong→
Director/Board Member
Age 50Since 2021-09-30
JS
John Shannon→
Chairman
Age 64Since 2026-06-30
JB
James Brady→
Director/Board Member
Age 63Since 2025-03-27
NK
Nerissa Kreher→
Director/Board Member
Age 53Since 2026-06-30
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| BlackRock Advisors LLC | 7.025 % | 12,128,400 |
| D.E. Shaw & Co., Inc. | 4.512 % | 7,788,811 |
| Vanguard Capital Management LLC | 4.044 % | 6,980,882 |
| STATE STREET CORPORATION | 2.698 % | 4,658,174 |
| Geode Capital Management LLC | 2.485 % | 4,290,629 |
Catalog · 2026-07-09
Registry officers13
| Name | Role | Since | Shares |
|---|---|---|---|
| Anh Nguyen | Chief Tech/Sci/R&D Officer | 2025-02-23 | - |
| John Shannon | Chairman | 2026-06-30 | - |
| John Shannon | Chief Executive Officer | 2024-07-31 | - |
| Marla Persky | Chairman | 2024-07-31 | - |
| Steven Pieper | Director of Finance/CFO | 2021-09-30 | - |
| Barbara-Jean Bormann-Kennedy | Director/Board Member | 2021-10-04 | - |
| Dawn Halkuff | Director/Board Member | 2021-10-04 | - |
| Garheng Albert Kong | Director/Board Member | 2021-09-30 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 12.86Range 8–18Analysts 7
8Mean 12.8618
- Strong buy 1
- Buy 5
- Hold 1
Broker actions40 of 42
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | 14 | 2026-10-06 |
| Leerink Partners | Maintained | Outperform | 16 | 2026-09-10 |
| Barclays | Maintained | Overweight | 12 | 2026-08-20 |
| HC Wainwright & Co. | Reiterated | Buy | 10 | 2026-03-02 |
| HC Wainwright & Co. | Reiterated | Buy | 10 | 2026-01-09 |
| Barclays | Initiated | Overweight | 9 | 2025-12-09 |
| Oppenheimer | Maintained | Outperform | 18 | 2025-11-07 |
| HC Wainwright & Co. | Maintained | Buy | 10 | 2025-11-07 |
| Piper Sandler | Maintained | Neutral | 8 | 2025-11-07 |
| Oppenheimer | Maintained | Outperform | 18 | 2025-10-29 |
| HC Wainwright & Co. | Maintained | Buy | 10 | 2025-09-17 |
| Leerink Partners | Maintained | Outperform | 9 | 2025-08-19 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.